Helsinn to Present at UBS Healthcare Conference in New York

Helsinn to Present at UBS Healthcare Conference in New York

 

Lugano, Switzerland, May 23, 2016 – Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is pleased to announce that William Mann, President and Chief Executive Officer of Helsinn’s U.S. subsidiary, Helsinn Therapeutics (U.S.) Inc., will present at the UBS Healthcare Conference at the Grand Hyatt in New York City. His overview of the Helsinn Group will include an update on Helsinn’s U.S. business and will take place on Monday 23rd May at 10:30am EDT.

About the Helsinn Group

Helsinn is a privately owned cancer supportive care pharmaceutical group with an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model working with long standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the United States, a representative office in China, as well as a product presence in about 90 countries globally.

In 2016, our 40th anniversary year, you can meet representatives from Helsinn at:

  • ASCO Annual Meeting (Chicago, USA, 3-7 June)
  • MASCC Annual Meeting (Adelaide, Australia, 23-25 June)
  • ChemOutsourcing Conference (Parsippany, New Jersey, 19-21 September)
  • CPhI Worldwide (Barcelona, Spain, 4-6 October)
  • ESMO Congress (Copenhagen, Denmark, 7-11 October)
  • BioEurope (Köln, Germany, 4-6 November)

For more information, please visit www.helsinn.com

Follow us on Twitter @HelsinnGroup

 

For more information, please contact:

 

Helsinn Group

Paola Bonvicini

Head of Communication & Press Office

Tel: +41 91-985-21-21

info-hhc@helsinn.com

 

 

As part of its patient-centered mission and support of the oncology community, Helsinn works closely with Patient Advocacy Groups. These key stakeholders protect the interests of cancer patients by helping them to receive appropriate and timely care, education, support and financial assistance, when needed.

Related Articles